Core Viewpoint - The recent controversy surrounding the ingredient EGF in the core brand Han Shu of Shangmei Co. has led to significant stock price fluctuations and raised concerns about the company's future growth plans [4][5][8]. Group 1: Company Developments - Chairman Lv Yixiong announced that executive director Luo Yan purchased 364,000 shares at approximately HKD 75.5 each, totaling about HKD 66.32 million, indicating strong confidence in the company's future [2]. - The company aims to achieve a revenue target of 30 billion yuan by 2030, requiring a doubling of current revenue within five years [12][38]. - In the first half of the year, the company's revenue reached 4.1 billion yuan, with a goal of hitting 10 billion yuan in annual revenue for the new brand Newpage [11][22]. Group 2: Controversy and Market Reaction - The controversy originated from the detection of EGF in two Han Shu face masks, leading to a significant drop in stock price, with a loss of over 10 billion yuan in market value [5][8]. - Han Shu's official response included presenting third-party testing results to refute the claims, but investor concerns persisted, resulting in a 30% drop in stock price on the first trading day after the holiday [8][39]. - The Chinese Fragrance and Cosmetic Industry Association noted that there is currently no commercial ELISA kit available for testing EGF in cosmetics, which complicates the situation [9]. Group 3: Strategic Expansion Plans - The company is in a critical expansion phase, planning to launch 20 new brands between 2025 and 2027, primarily leveraging the Douyin platform for marketing [10][22]. - The company is also focusing on international markets, with a significant investment of 300 million yuan in a factory in Southeast Asia [24]. - The strategy includes hiring top talent and implementing a rigorous selection process to enhance brand development and marketing effectiveness [29][32].

Core Viewpoint - Guojin Securities has initiated coverage on Shumei Co., Ltd. (02145), recognizing it as a leading player in China's beauty and personal care industry, with a multi-brand matrix across skincare, baby care, and hair care sectors. The company primarily utilizes online channels and is expected to achieve strong growth, particularly with its main brand, Han Shu, and new brand development, leading to a target price of HKD 109.78 based on a 2025 PE of 30 times, with a "Buy" rating assigned [1]. Group 1: Company Development and Strategy - The company's multi-brand expansion strategy shares similarities with Anta Sports, focusing on market-driven approaches, precise brand positioning, and effective marketing to quickly address consumer pain points [2]. - The trend of refined channel operations is evident as the company restructures its channel strategy around Douyin, leveraging innovative marketing and increasing self-broadcasting to achieve significant revenue and profit growth [2]. - The company ensures a steady supply of core management talent through a dual approach of internal training and external recruitment, which supports differentiated development across its brands [2]. Group 2: Growth Projections and Market Position - The company is expected to achieve substantial growth in its three main segments: skincare, baby care, and hair care, with Han Shu projected to exceed CNY 10 billion in revenue within three years [3]. - In the skincare segment, Han Shu has seen a significant market share increase through Douyin, with projected revenue growth of over 80% in 2024, despite a slowdown in H1 2025 due to channel adjustments [3]. - The baby care brand, Yiye, is experiencing rapid growth with a unique "medical research co-creation" model, expected to achieve a compound annual growth rate of over 50% in the next three years [3]. - The hair care segment is anticipated to produce major brands, with a focus on clear positioning and consumer mindset development, as well as entering faster-growing segments like anti-hair loss [3]. Group 3: Financial Forecasts - The company achieved an online sales ratio of nearly 93% in H1 2025, with Han Shu's rapid growth through Douyin contributing to projected revenues of CNY 5.591 billion in 2024, reflecting an 80.9% year-on-year increase [4]. - New brands like Yiye are also rapidly gaining traction, with projected growth rates of 498% for 2023 and 146% for H1 2025 [4]. - Earnings per share (EPS) forecasts for 2025-2027 are estimated at CNY 2.68, CNY 3.33, and CNY 4.09, respectively, with a valuation of 24 times for 2026 [4].

Core Viewpoint - Guojin Securities has initiated coverage on Shangmei Co., Ltd. (02145), recognizing it as a leading player in China's beauty and personal care industry, with a multi-brand matrix across skincare, baby care, and hair care sectors. The company is primarily focused on online channels, and given the strong growth potential of its multi-brand strategy, it has set a target price of HKD 109.78 based on a 30x PE valuation for 2025, rating it as "Buy" [1]. Group 1: Company Development and Strategy - The company's multi-brand expansion strategy shares similarities with Anta Sports, focusing on market-driven approaches that quickly identify consumer pain points and launch targeted products while leveraging impactful marketing and top-tier IP collaborations [1]. - The trend of refined channel operations is evident as the company restructures its channel strategy around Douyin, enhancing revenue and profit growth through innovative marketing and increased self-broadcasting [1]. - The company ensures a steady supply of core management talent through a dual approach of internal training and external recruitment, which supports differentiated development across its brands [1]. Group 2: Growth Projections - The company is expected to achieve significant growth in its three main segments: skincare, baby care, and hair care, with projections indicating that Han Shu could surpass CNY 10 billion in revenue within three years [2]. - In the skincare segment, Han Shu has seen a notable increase in market share through Douyin, with projected revenue growth exceeding 80% in 2024. Despite a slowdown in H1 2025 due to channel adjustments, Q3 2025 GMV is expected to grow by 50% year-on-year [2]. - The baby care brand, Yiye, is experiencing rapid growth with a projected compound annual growth rate (CAGR) exceeding 50% over the next three years, while the hair care segment is anticipated to produce major brands by leveraging clear positioning and consumer engagement strategies [2]. Group 3: Financial Forecasts - The company is projected to achieve a revenue of CNY 5.591 billion in 2024, reflecting an 80.9% year-on-year increase, with H1 2025 revenue expected to grow by 14.3% to CNY 3.344 billion [3]. - New brands like Yiye are rapidly gaining traction, with annual growth rates of 498% in 2023 and 146% in 2024, and a continued strong performance expected in H1 2025 [3]. - Earnings per share (EPS) forecasts for 2025-2027 are estimated at CNY 2.68, CNY 3.33, and CNY 4.09, respectively, with a valuation of 24x for 2026 [3].

Investment Rating - The report gives a "Buy" rating for the cosmetics and medical beauty industry, highlighting potential growth opportunities in the sector [4][13]. Core Insights - The cosmetics and medical beauty sector is currently underperforming compared to the market, with the Shenwan Beauty Care Index rising by only 0.5% from November 21 to November 28, 2025, which is lower than the overall market performance [5][4]. - The sixth China Cosmetics Annual Conference emphasized the importance of multi-brand globalization and AI empowerment for future development, with industry leaders discussing strategies for growth and market adaptation [10][4]. - The report anticipates that domestic brands will thrive during the industry's consolidation phase, leveraging innovation and consumer demand to drive growth [11][4]. Summary by Sections Industry Performance - The cosmetics and medical beauty sector has shown weak performance, with the Shenwan Cosmetics Index increasing by 1.4%, which is 1.6 percentage points lower than the Shenwan A Index [5][4]. - Key stocks in the sector include Yanjiang Co. (+22.0%), Mingchen Health (+17.9%), and Lihe Technology (+9.9%) [6][4]. Market Trends - The report identifies trends such as the need for brands to localize when expanding internationally, the role of AI in upgrading the industry, and the focus on men's skincare and body care segments [10][4]. - The medical beauty market is expected to see growth driven by new products and consumer demand, despite some economic pressures [12][4]. Company Analysis - Qingmu Technology is highlighted as a leading player in the full-service e-commerce operation sector, with a strong focus on data and technology to drive growth [16][4]. - The report notes that the company has shown significant revenue growth, with projected revenues of 15.1 billion, 19.0 billion, and 23.4 billion yuan for 2025-2027, respectively [19][4]. Investment Recommendations - Recommended stocks include brands with strong channel and brand matrices such as Maogeping, Shuangmei, and Proya, as well as companies in the medical beauty sector like Aimeike [13][4]. - The report suggests focusing on companies with strong R&D capabilities and a broad product pipeline, particularly in the medical beauty segment [13][4].

Core Insights - Southbound funds increased their holdings in Shangmei Co., Ltd. by 198,700 shares on November 4, 2025, marking a 0.46% increase in total shares held [1][2] - Over the past five trading days, there have been four days of net increases in holdings, totaling 1,330,800 shares [1][2] - In the last twenty trading days, there were ten days of net increases, amounting to 1,400,500 shares [1][2] - As of now, southbound funds hold 43,388,700 shares of Shangmei Co., Ltd., which represents 21.02% of the company's total issued ordinary shares [1][2] Company Overview - Shangmei Co., Ltd. is primarily engaged in the production and sale of cosmetics in China [2] - The company markets brands such as "Han Shu," "Yi Ye Zi," and "Red Elephant," focusing on skincare and maternal and infant care products [2] - Products are sold through both online and offline channels, with a primary focus on the domestic market [2]

Core Viewpoint - Southbound funds have reduced their holdings in Shangmei Cosmetics Co., Ltd. (02145.HK), indicating a trend of net selling over recent trading days [1] Group 1: Shareholding Changes - On October 22, southbound funds reduced their holdings by 12,100 shares, marking a decrease of 0.03% [2] - Over the past five trading days, there have been four days of net selling, totaling a reduction of 742,100 shares [1][2] - In the last 20 trading days, there were 12 days of net selling, with a cumulative reduction of 1,188,800 shares [1] Group 2: Current Holdings - As of now, southbound funds hold 41,123,600 shares of Shangmei Cosmetics, which represents 19.92% of the company's total issued ordinary shares [1][2] Group 3: Company Overview - Shangmei Cosmetics Co., Ltd. primarily engages in the production and sale of cosmetics, with key brands including "Han Shu," "Yi Ye Zi," and "Red Elephant" [2] - The company's products are utilized for skincare and maternal and infant care, sold through both online and offline channels [2] - The company mainly operates in the domestic market [2]

Core Insights - Southbound funds increased their holdings in Shangmei Cosmetics Co., Ltd. by 34,900 shares on October 14, 2025, bringing the total holdings to 41,631,900 shares, which represents 20.17% of the company's issued ordinary shares [1][2] Summary by Category Shareholding Changes - Over the past five trading days, southbound funds have reduced their holdings on three occasions, with a total net reduction of 327,900 shares [1] - In the last twenty trading days, there were ten days of reductions, resulting in a cumulative net decrease of 223,600 shares [1] - The most recent trading day on October 13, 2025, saw a decrease of 49,500 shares, representing a change of -0.12% [2] Company Overview - Shangmei Cosmetics Co., Ltd. primarily engages in the production and sale of cosmetics, with key brands including "Hansu," "Yiyezi," and "Red Elephant" [2] - The company's products cater to skincare and maternal and infant care, distributed through both online and offline channels [2] - The company mainly operates within the domestic market of China [2]

Investment Rating - The report initiates coverage with a "Buy" rating for Shuiyang Co., Ltd. [3][13] Core Insights - The cosmetics and medical beauty sector underperformed the market, with the Shenwan Beauty Care Index increasing by 0.2% from September 5 to September 12, 2025, lagging behind the Shenwan A Index by 2.7 percentage points [3][4] - Domestic cosmetics brands showed strong growth in August, with key brands under Shumei Co. achieving a 70% growth rate on Douyin and Taobao platforms, indicating a robust performance despite high base effects [3][9] - The report highlights the upcoming Double 11 shopping festival, suggesting that brands should prepare for promotional strategies [3][9] Summary by Sections Industry Performance - The cosmetics and medical beauty sector's performance was weaker than the market, with declines in the Shenwan Cosmetics Index by 0.5% and the Shenwan Personal Care Index by 0.8% during the specified period [3][4] Key Company Review - Shuiyang Co., Ltd. is positioned as a leading technology-driven beauty company in China, with stable revenue between 4 to 5 billion yuan from 2021 to 2024 and an expected gross margin of 63.01% in 2024, up by 10.94 percentage points from 2021 [3][10] - The company has a dual business model of proprietary brands and CP agency brands, with a strong focus on high-end and global market transformation [3][10][12] E-commerce Data - In August, key domestic brands on Douyin and Taobao platforms showed significant growth, with Shumei Co. brands achieving a 70% increase, and other brands like Maogeping and Runben also reporting substantial growth rates [3][14] Market Trends - The report notes that the overall retail sales of cosmetics in July 2025 grew by 4.5%, indicating a recovery in consumer spending [3][17] - The domestic skincare market is projected to reach 271.2 billion yuan in 2024, despite a slight decline of 3.7% year-on-year, with domestic brands gaining market share [3][26] Company Announcements - Shumei Co. has appointed Dr. Karl Lintner, a pioneer in peptide beauty, as the chief scientific advisor, aiming to enhance its global competitiveness in research and development [3][21]

Group 1 - The company reported a robust revenue growth of 17.29% year-on-year, achieving an operating income of 4.108 billion yuan in H1 2025 [1] - The net profit attributable to the parent company reached 524 million yuan, reflecting a significant increase of 30.65% year-on-year [1] - The gross margin for H1 2025 was 75.52%, a slight decrease of 0.99 percentage points, while the net profit margin improved by 1.74 percentage points to 13.52% [1] Group 2 - The main brand, Han Shu, generated revenue of 3.344 billion yuan in H1 2025, marking a 14.3% increase, with significant sales from the Hong Man Yao and X Peptide series [2] - The second brand, Newpage, saw a remarkable revenue growth of 146.5% year-on-year, reaching 397 million yuan, achieving its annual sales target for 2024 [2] - The company is actively enhancing its online sales strategy, with self-operated online channels generating 3.421 billion yuan in revenue, a 24.6% increase, and accounting for 83.3% of total revenue [2] Group 3 - The company is expected to achieve net profits of 1.025 billion yuan, 1.286 billion yuan, and 1.566 billion yuan for the years 2025, 2026, and 2027, respectively, with corresponding PE ratios of 32, 26, and 21 [3]

Core Viewpoint - The company reported strong financial performance in H1 2025, with revenue of 4.108 billion yuan, a year-on-year increase of 17.3%, and a net profit of 556 million yuan, up 34.7% [1][2]. Group 1: Financial Performance - Revenue breakdown by brand shows that Han Shu generated 3.344 billion yuan, accounting for 81.4% of total revenue, with a year-on-year growth of 14.3% [1]. - Newpage achieved revenue of 397 million yuan, a significant increase of 146.5%, representing 9.6% of total revenue, driven by strong sales of its star products [1]. - One Leaf reported revenue of 89 million yuan, a decline of 29.0%, making up 2.2% of total revenue due to transformation adjustments [1]. - Red Little Elephant generated 159 million yuan, down 8.7%, accounting for 3.9% of total revenue, with a narrowing decline as brand strength improves [1]. Group 2: Strategic Initiatives - The company is implementing a "Six Six Strategy" focusing on six major sectors: mass skincare, maternal & child care, personal care, color cosmetics, functional skincare, and high-end skincare, aiming for sustainable development [2]. - The company’s gross margin decreased by 1.0 percentage points to 75.5%, while the net profit margin increased by 1.7 percentage points to 13.5%, indicating improved profitability [2]. - Sales expense ratio decreased by 0.7 percentage points to 56.9%, reflecting the release of scale effects [2]. Group 3: Future Outlook - The company forecasts net profits of 1.02 billion yuan, 1.28 billion yuan, and 1.55 billion yuan for 2025-2027, with year-on-year growth rates of 31.1%, 25.3%, and 20.9% respectively [2]. - The strong performance of the main brand Han Shu on Douyin has established significant brand momentum, with potential for other brands to replicate this success [2].